Cargando…

A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma

For patients with localized pancreatic cancer with minimal vascular involvement, optimal survivability requires a multidisciplinary approach of surgical resection and systemic chemotherapy. FOLFIRINOX is a combination chemotherapy regimen that offers promising results in the perioperative and metast...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singhal, Ruchi, Rogers, Sherise C, Lee, Ji-Hyun, Ramnaraign, Brian, Sahin, Ilyas, Fabregas, Jesus C, Thomas, Ryan M., Hughes, Steven J, Nassour, Ibrahim, Hitchcock, Kathryn, Russell, Karen, Kayaleh, Omar, Turk, Anita, Zlotecki, Robert, DeRemer, David L, George, Thomas J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2023
Materias:	Clinical Trial Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594143/ https://www.ncbi.nlm.nih.gov/pubmed/37753702 http://dx.doi.org/10.2217/fon-2023-0256

Ejemplares similares

Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase
por: Sachdev, Jasgit C., et al.
Publicado: (2020)

Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S‐1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma
por: Akahori, Takahiro, et al.
Publicado: (2019)

A Phase I Trial of Oxaliplatin, Irinotecan, and S‐1 Combination Therapy (OX‐IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403)
por: Kawamoto, Yasuyuki, et al.
Publicado: (2021)

A case of pathological complete response with liposomal irinotecan + 5-FU/LV for unresectable locally advanced pancreatic cancer
por: Kikuchi, Koji, et al.
Publicado: (2022)

Importance of carbohydrate antigen (CA 19-9) and carcinoembrionic antigen (CEA) in the prognosis of patients with duodenal adenocarcinoma: a retrospective single-institution cohort study
por: Altshuler, Ellery, et al.
Publicado: (2023)

Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
por: Folprecht, Gunnar, et al.
Publicado: (2014)

Evaluation of Anticancer Activity of Zhubech, a New 5-FU Analog Liposomal Formulation, against Pancreatic Cancer
por: Ndemazie, Nkafu Bechem, et al.
Publicado: (2023)

Pan-drug and drug-specific mechanisms of 5-FU, irinotecan (CPT-11), oxaliplatin, and cisplatin identified by comparison of transcriptomic and cytokine responses of colorectal cancer cells
por: Carlsen, Lindsey, et al.
Publicado: (2021)

Clinically Relevant Drug Interactions in the Cancer Setting
por: DeRemer, David
Publicado: (2022)

Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial
por: Macarulla Mercadé, Teresa, et al.
Publicado: (2020)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial
por: Madi, A, et al.
Publicado: (2012)

A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial
por: Simionato, Francesca, et al.
Publicado: (2020)

Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma
por: Granda, T G, et al.
Publicado: (2002)

Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
por: Aparicio, T, et al.
Publicado: (2003)

Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
por: Alliot, C, et al.
Publicado: (2004)

Acute Immune-Mediated Thrombocytopenia due to Oxaliplatin and Irinotecan Therapy
por: Tam, Eric L., et al.
Publicado: (2019)

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer
por: Ma, Cynthia X., et al.
Publicado: (2012)

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer
por: Adiwijaya, BS, et al.
Publicado: (2017)

Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans
por: Telisnor, Guettchina, et al.
Publicado: (2023)

A scoping review on the relationship between race/ethnicity and the receipt of supportive care medications during cancer treatment: Implications for the clinical pharmacist
por: Awunti, MegCholack, et al.
Publicado: (2022)

TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases
por: Anders, Carey, et al.
Publicado: (2014)

Irinotecan Plus S-1 Followed by Hepatectomy for a Patient with Initially Unresectable Colorectal Liver Metastases, Who Showed Severe Drug Rash with Oxaliplatin Plus 5-FU and Leucovorin (FOLFOX)
por: Komori, Hiroyuki, et al.
Publicado: (2014)

Reply: Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
por: Aparicio, T, et al.
Publicado: (2004)

Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma
por: Di Lauro, L, et al.
Publicado: (2007)

Oxaliplatin but Not Irinotecan Impairs Posthepatectomy Liver Regeneration in a Murine Model
por: Soriano, Perry A., et al.
Publicado: (2011)

Translational Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Oxaliplatin and Irinotecan in Colorectal Cancer
por: Zhu, Jinwei, et al.
Publicado: (2023)

Liposomal Irinotecan Shows a Larger Therapeutic Index than Non-liposomal Irinotecan in Patient-Derived Xenograft Models of Pancreatic Cancer
por: Barbier, Sandrine, et al.
Publicado: (2023)

Sphingomyelin Liposomes Containing Porphyrin-phospholipid for Irinotecan Chemophototherapy
por: Carter, Kevin A, et al.
Publicado: (2016)

Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
por: Frampton, James E.
Publicado: (2020)

Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs
por: Milano, Gérard, et al.
Publicado: (2022)

A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer
por: Segar, Jennifer M., et al.
Publicado: (2019)

Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma
por: Yu, Kenneth H., et al.
Publicado: (2023)

Prognosis and Treatment Outcomes of Bone Metastasis in Gallbladder Adenocarcinoma: A SEER-Based Study
por: Gera, Kriti, et al.
Publicado: (2023)

Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer
por: Liu, Ying, et al.
Publicado: (2015)

UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Petrioli, R, et al.
Publicado: (2004)

UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Alliot, C
Publicado: (2004)

Effects of Clinical and Tumor Characteristics on Survival in Patients with Hepatocellular Carcinoma with Bone Metastasis
por: Ozer, Muhammet, et al.
Publicado: (2023)

Unraveling Racial Disparities in Supportive Care Medication Use among End-of-Life Pancreatic Cancer Patients: Focus on Pain Management and Psychiatric Therapies
por: Allen, John M., et al.
Publicado: (2023)

Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data
por: Buhl, Ida Kappel, et al.
Publicado: (2016)

Carcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5FU in colorectal cancer cells
por: Gonçalves-Ribeiro, Samuel, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6fl05hvsmcqvn4n5duijuen64p